• 1. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 4. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acid esters
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzoic acid esters

Recent Advances in the Study of Methyl 2,5-difluoro-4-hydroxybenzoate (CAS: 1261684-74-5) in Chemical Biology and Pharmaceutical Research

Methyl 2,5-difluoro-4-hydroxybenzoate (CAS: 1261684-74-5) has recently emerged as a compound of significant interest in chemical biology and pharmaceutical research. This fluorinated benzoate derivative has been the subject of multiple studies due to its potential applications in drug discovery and development. Recent literature highlights its role as a key intermediate in the synthesis of novel bioactive molecules, particularly in the development of enzyme inhibitors and receptor modulators.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the utility of Methyl 2,5-difluoro-4-hydroxybenzoate in the synthesis of selective COX-2 inhibitors. The researchers utilized this compound as a building block to create a series of derivatives with improved anti-inflammatory properties and reduced gastrointestinal side effects compared to traditional NSAIDs. The presence of fluorine atoms at the 2 and 5 positions was found to significantly enhance metabolic stability and bioavailability of the resulting compounds.

In the field of antimicrobial research, a recent investigation published in Bioorganic & Medicinal Chemistry Letters (2024) explored the antibacterial activity of Methyl 2,5-difluoro-4-hydroxybenzoate derivatives against drug-resistant bacterial strains. The study reported that certain modifications to the parent compound yielded molecules with potent activity against MRSA and ESBL-producing E. coli, suggesting potential applications in addressing antibiotic resistance challenges.

Structural analysis studies using X-ray crystallography and NMR spectroscopy have provided new insights into the molecular interactions of Methyl 2,5-difluoro-4-hydroxybenzoate derivatives. A 2023 Nature Communications paper revealed how the specific fluorine substitution pattern influences hydrogen bonding networks and molecular packing in crystal structures, which has important implications for drug formulation and solid-state properties.

Recent advances in synthetic methodology have also improved access to Methyl 2,5-difluoro-4-hydroxybenzoate and its derivatives. A 2024 Organic Process Research & Development publication described a novel, scalable synthesis route that significantly reduces production costs while maintaining high purity standards. This development is particularly important for potential large-scale pharmaceutical applications.

Ongoing research continues to explore the therapeutic potential of Methyl 2,5-difluoro-4-hydroxybenzoate-based compounds in various disease areas, including oncology, neurodegenerative disorders, and metabolic diseases. Preliminary results from several preclinical studies suggest promising activity profiles, though further investigation is needed to fully evaluate efficacy and safety.

• 1214324-64-7(Methyl 2-fluoro-3-hydroxybenzoate)
• 105836-28-0(Benzoic acid, 2-fluoro-3-hydroxy-, ethyl ester)
• 1214324-50-1(Methyl 3,6-difluoro-2-hydroxybenzoate)
• 1261894-21-6(Methyl 2-fluoro-4-(4-fluoro-3-hydroxyphenyl)benzoate)
• 194938-88-0(Methyl 2,6-difluoro-4-hydroxybenzoate)
• 137234-92-5(Methyl 2,4,5-trifluoro-3-hydroxybenzoate)
• 194804-80-3(2,4-Difluoro-3-hydroxybenzoic Acid Methyl Ester)
• 1214332-41-8(Methyl 2,6-difluoro-3-hydroxybenzoate)
• 1261894-17-0(Methyl 2-fluoro-4-(3-fluoro-4-hydroxyphenyl)benzoate)
• 197507-22-5(Methyl 2-fluoro-4-hydroxybenzoate)